<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953156</url>
  </required_header>
  <id_info>
    <org_study_id>AP2105-50107</org_study_id>
    <nct_id>NCT04953156</nct_id>
  </id_info>
  <brief_title>Nitroglycerine Versus Dexmedetomidine Infusion in Intraoperative Management of Uncontrolled Hypertension</brief_title>
  <official_title>A Comparative Study Between Nitroglycerine Infusion and Dexmedetomidine Infusion in Intraoperative Management of Uncontrolled Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim to compare the efficacy of intraoperative dexmedetomidine infusion versus&#xD;
      Nitroglycerin infusion in cancer patients with accidental uncontrolled intraoperative&#xD;
      elevation of blood pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nitroglycerine is a direct vessel wall vasodilator with more venodilator effect than arterial&#xD;
      dilator effect. It is used as an anti-anginal and antihypertensive drug. On the other hand,&#xD;
      dexmedetomidine is a highly selective alpha 2 adrenergic agonist with sympatholytic effect.&#xD;
      This study aim to compare the efficacy of intraoperative dexmedetomidine infusion versus&#xD;
      Nitroglycerin infusion in cancer patients with accidental uncontrolled intraoperative&#xD;
      elevation of blood pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative blood pressure values</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>measurements of blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative heart rate values</measure>
    <time_frame>operative time</time_frame>
    <description>measurements of intraoperative heart rate</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nitroglycerin</arm_group_label>
    <description>data of patients meeting the eligibility criteria and received nitroglycerine infusion will be retrieved from medical records.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <description>patients will receive dexmedetomidine bolus dose of 1 mic/kg over 20 minutes followed by intravenous infusion of 0.2-0.7 mic/kg/hr adjusted according to each patient hemodynamic response</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin</intervention_name>
    <description>data will be retrieved from intraoperative medical records for the period from May 2020 to May 2021 for patients meeting the eligibility criteria who developed uncontrolled elevation of their blood pressure and received nitroglycerine infusion</description>
    <arm_group_label>Nitroglycerin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>All patients who develop uncontrolled elevation of their blood pressure and meeting the eligibility criteria from July 2021 to July 2022 will receive dexmedetomidine bolus of 1mic/kg over 20 minutes and then continuous infusion of 0.2-0.7 mic/kg/hour adjusted according to each patient hemodynamic response.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients with controlled hypertension and undergoing surgical procedures under&#xD;
        general anesthesia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cancer patients with controlled hypertension and undergoing surgical procedures under&#xD;
             general anesthesia&#xD;
&#xD;
          -  â‰¥ Age 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient refusal&#xD;
&#xD;
          -  patients on Beta blockers&#xD;
&#xD;
          -  kidney or liver function impairment&#xD;
&#xD;
          -  bradycardia, any degree of heart block and severe cardiorespiratory disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walaa Y Elsabeeny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer of Anesthesia and Pain Management, National Cancer Institute, Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walaa Y Elsabeeny, MD</last_name>
    <phone>01007798466</phone>
    <phone_ext>+2</phone_ext>
    <email>walaa.elsabeeny@nci.cu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walaa Y Elsabeeny, MD</last_name>
      <phone>01007798466</phone>
      <phone_ext>+2</phone_ext>
      <email>walaa.elsabeeny@nci.cu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Walaa Youssef Elsabeeny</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia and Pain management</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>data will be available upon reasonable request through contacting the principle investigator</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

